Immunological and molecular characterization of an aggressive murine lymphoma variant: modulation in vitro and in vivo.

Important note: Information in this article was accurate in 1999. The state of the art may have changed since the publication date.

Immunological and molecular characterization of an aggressive murine lymphoma variant: modulation in vitro and in vivo.

Int J Oncol. 1999 Jul;15(1):71-9. Unique Identifier : AIDSLINE MED/99307655
Jurianz K; von Hoegen P; Schirrmacher V; Division of Cellular Immunology, German Cancer Research Center,; D-69120 Heidelberg, Germany.

Abstract: The highly metastatic murine ESb-L lymphoma was analyzed with respect to its possible origin and phenotype modulation. By determining the methylation status of the CD8 gene an early thymic origin of the ESb-L lymphoma cells is suggested. It revealed that the precursors of ESb-L cells had at least one CD8 allele expressed during their development. ESb-L tumor cells were found to express ICAM-1, ICAM-2, VLA-4 and Mel14 as adhesion molecules and homing receptors and CD25, CD69 and CD124 (HSA) as T-cell related activation markers. PCR analysis revealed that ESb-L tumor cells express a Th2-like cytokine pattern with mRNAs for IL-4, IL-5, IL-6, IL-10 and IL-13, but not for IL-2 and IFNgamma. In addition mRNA for TNFalpha, LT, IFNalpha and the chemokines MIP1alpha and MIP1beta was found. The expression of the adhesion molecules ICAM-1, ICAM-2, VLA-4 and of the T-cell activation marker CD25 on ESb-L tumor cells could be upregulated by incubating the cells with 10 ng/ml TNFalpha. For CD25 this effect was confirmed also at the mRNA level. Using the lacZ transduced T-cell lymphoma ESb-L-CI we were able to re-isolate live tumor cells from the primary site or from a metastasized liver and to investigate their phenotype ex vivo. MIP1alpha mRNA expression was strongly reduced in ex vivo isolated tumor cells as compared to in vitro grown cells indicating the modulatory role of the tumor microenvironment. The presented data suggest possible roles of TNFalpha and/or other microenvironmental factors modulating the expression of molecules involved in cell migration and adhesion thereby influencing cancer metastasis.

Keywords: JOURNAL ARTICLE Animal Antigens, CD8/ANALYSIS Cell Adhesion Molecules/BIOSYNTHESIS Cell Lineage Disease Progression DNA Methylation DNA, Neoplasm/CHEMISTRY Gene Expression Regulation, Neoplastic Immunophenotyping Lymphocyte Transformation Lymphokines/SECRETION Lymphoma, T-Cell/GENETICS/IMMUNOLOGY/METABOLISM/*PATHOLOGY Mice Mice, Inbred DBA Neoplasm Metastasis Neoplasm Proteins/SECRETION Polymerase Chain Reaction RNA, Messenger/BIOSYNTHESIS RNA, Neoplasm/BIOSYNTHESIS Thymus Gland/PATHOLOGY Th2 Cells/PATHOLOGY/SECRETION Tumor Cells, Cultured
991030
A99A0918

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1999. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1999. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .